FDA Approves Sunharbo to Prevent Stroke in Certain High-Risk Adults

The FDA has approved Bayer HealthCare Pharmaceuticals Inc.’s Sunharbo (asundexian) 50 mg tablets for use in combination with antiplatelet therapy to reduce the risk of stroke in adults with a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

Source:FDA · Read original